A Novel AS1411 Aptamer-Based Three-Way Junction Pocket DNA Nanostructure Loaded with Doxorubicin for Targeting Cancer Cells in Vitro and in Vivo

Taghdisi, Seyed Mohammad; Danesh, Noor Mohammad; Ramezani, Mohammad; Yazdian-Robati, Rezvan; Abnous, Khalil

doi:10.1021/acs.molpharmaceut.8b00124

Cited by 71 publications

(36 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Next, we investigated whether aptamer-modified NPs could differentiate between the CT26 target cells (CT26) and a control cell line (CHO) that had low nucleolin expression. 20 , 42 Apt-NPs-cou6 or NPs-cou6 were incubated with either the nucleolin-positive CT26 or the nucleolin-negative CHO cells, which were subsequently evaluated by confocal microscopy. In CT26 cells, the green fluorescence was much stronger when treated with Apt-NPs-cou6 vs NPs-cou6.…”

Section: Resultsmentioning

confidence: 99%

<p>Targeted Treatment of Colon Cancer with Aptamer-Guided Albumin Nanoparticles Loaded with Docetaxel</p>

Yu¹,

Li²,

Duan³

et al. 2020

IJN

View full text Add to dashboard Cite

Purpose Chemotherapy of colon cancer needs improvement to mitigate the severe adverse effects (AEs) associated with the cytotoxic drugs. The aim of this study is to develop a novel targeted drug delivery system (TDDS) with practical application potential for colon cancer treatment. Methods The TDDS was built by loading docetaxel (DTX) in albumin nanoparticles (NPs) that were functionalized with nucleolin-targeted aptamers (AS1411). Results The TDDS (Apt-NPs-DTX) had an average size of 62 nm and was negatively charged with a zeta potential of −31.2 mV. DTX was released from the albumin NP with a typical sustained release profile. Aptamer-guided NPs were preferentially ingested by nucleolin-expressing CT26 colon cancer cells vs the control cells. In vitro cytotoxicity study showed that Apt-NPs-DTX significantly enhanced the killing of CT26 colon cancer cells. Importantly, compared with non-targeted drug delivery, Apt-NPs-DTX treatment significantly improved antitumor efficacy and prolonged the survival of CT26-bearing mice, without raising systemic toxicity. Conclusion The results suggest that Apt-NPs-DTX has potential in the targeted treatment of colon cancer.

show abstract

Section: Resultsmentioning

confidence: 99%

<p>Targeted Treatment of Colon Cancer with Aptamer-Guided Albumin Nanoparticles Loaded with Docetaxel</p>

Yu¹,

Li²,

Duan³

et al. 2020

IJN

View full text Add to dashboard Cite

show abstract

“…b) A DOX‐loaded DNA nanostructure, and fluorescence images of both control CHO cells (above) and PC‐3 cells (below) with or without treatment of the nanostructure. Reproduced with permission . Copyright 2018, American Chemical Society.…”

Section: Dna/rna Aptamer‐conjugated Nanomaterialsmentioning

confidence: 99%

“…A three‐way junction pocket DNA nanostructure with the AS1411 aptamer self‐assembled with PEG as a linker was reported, which had DOX‐loading capacity for targeted drug delivery to PC‐3 (human prostate cancer) and 4T1 cells that highly express nucleolin (Figure 16b). PDT agents have also been developed using Zn‐porphyrin complexes for targeted transmembrane tyrosine kinase receptor HER2 sensing with simultaneous breast cancer therapeutic potential (Figure 16c).…”

Section: Dna/rna Aptamer‐conjugated Nanomaterialsmentioning

confidence: 99%

Bio‐Conjugated Advanced Materials for Targeted Disease Theranostics

Kwon

Yan

et al. 2020

Adv Funct Materials

View full text Add to dashboard Cite

Human beings are “machines” that use endogenously produced biomolecules as “components” in signaling and for the maintenance of the body. These biomolecules consist of proteins, nucleic acids, and carbohydrates, which can either be extracted from biological substrates or synthesized by chemical/biochemical methods. These biomolecules have the ability to recognize/interact with other biomolecules that are overexpressed in disease cells. For targeted theranostics, strategies to chemically incorporate these natural biomolecules with advanced materials to treat human diseases by imaging‐guided drug delivery or photodynamic/photothermal therapy are proposed, with improved biocompatibility. Herein, recent research on construction of quantum dots, nanoparticles, and 2D material platforms decorated with antibodies, peptides, nucleic acid aptamers, carbohydrates, and folic acid for targeted diagnosis and treatment are summarized and discussed. In addition, the various strategies required to construct effective functional materials for targeted cancer therapy are highlighted. The hope is that this review can inspire and guide those that are interested in the field of biomedicine to rationally design and develop new target‐based theranostic materials.

show abstract

“…After the nanoparticle was internalized, the pH-responsive polymer dissociated within the endosome and the drug and aptamer were released [ 14 ]. In 2018, Taghdisi et al described a DNA nanostructure comprised of three strands of the AS1411 aptamer for nucleolin which contained several double-helix sites where doxorubicin could intercalate [ 24 ]. The aptamer portions of the structure were able to bind nucleolin and cause the structure to be internalized, at which point protonation of doxorubicin caused the drug to be released [ 24 ].…”

Section: Combination Of Aptamers With Ph-responsive Systems For Drmentioning

confidence: 99%

pH-Control in Aptamer-Based Diagnostics, Therapeutics, and Analytical Applications

Belleperche

DeRosa

2018

Pharmaceuticals

View full text Add to dashboard Cite

Aptamer binding has been used effectively for diagnostics, in-vivo targeting of therapeutics, and the construction and control of nanomachines. Nanostructures that respond to pH by releasing or changing affinity to a target have also been used for in vivo delivery, and in the construction of sensors and re-usable nanomachines. There are many applications that use aptamers together with pH-responsive materials, notably the targeted delivery of chemotherapeutics. However, the number of reported applications that directly use pH to control aptamer binding is small. In this review, we first discuss the use of aptamers with pH-responsive nanostructures for chemotherapeutic and other applications. We then discuss applications that use pH to denature or otherwise disrupt the binding of aptamers. Finally, we discuss motifs using non-canonical nucleic acid base pairing that can shift conformation in response to pH, followed by an overview of engineered pH-controlled aptamers designed using those motifs.

show abstract

A Novel AS1411 Aptamer-Based Three-Way Junction Pocket DNA Nanostructure Loaded with Doxorubicin for Targeting Cancer Cells in Vitro and in Vivo

Cited by 71 publications

References 36 publications

<p>Targeted Treatment of Colon Cancer with Aptamer-Guided Albumin Nanoparticles Loaded with Docetaxel</p>

<p>Targeted Treatment of Colon Cancer with Aptamer-Guided Albumin Nanoparticles Loaded with Docetaxel</p>

Bio‐Conjugated Advanced Materials for Targeted Disease Theranostics

pH-Control in Aptamer-Based Diagnostics, Therapeutics, and Analytical Applications

Contact Info

Product

Resources

About